HLA-F | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	41 studies	43% ± 17%	Explore
CD8-positive, alpha-beta T cell	36 studies	41% ± 16%	Explore
B cell	32 studies	34% ± 12%	Explore
CD4-positive, alpha-beta T cell	32 studies	35% ± 13%	Explore
T cell	31 studies	33% ± 12%	Explore
regulatory T cell	24 studies	42% ± 11%	Explore
non-classical monocyte	22 studies	41% ± 17%	Explore
endothelial cell	21 studies	36% ± 11%	Explore
memory B cell	20 studies	37% ± 10%	Explore
mature NK T cell	19 studies	47% ± 15%	Explore
naive B cell	19 studies	31% ± 8%	Explore
gamma-delta T cell	18 studies	44% ± 15%	Explore
classical monocyte	18 studies	33% ± 12%	Explore
mucosal invariant T cell	17 studies	45% ± 16%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	17 studies	37% ± 9%	Explore
CD16-negative, CD56-bright natural killer cell, human	16 studies	47% ± 16%	Explore
conventional dendritic cell	16 studies	28% ± 12%	Explore
CD16-positive, CD56-dim natural killer cell, human	16 studies	56% ± 14%	Explore
macrophage	16 studies	26% ± 6%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	14 studies	50% ± 12%	Explore
dendritic cell	13 studies	32% ± 17%	Explore
monocyte	13 studies	27% ± 6%	Explore
CD8-positive, alpha-beta memory T cell	13 studies	49% ± 12%	Explore
plasmacytoid dendritic cell	12 studies	27% ± 10%	Explore
CD4-positive, alpha-beta memory T cell	12 studies	40% ± 10%	Explore
effector memory CD8-positive, alpha-beta T cell	12 studies	52% ± 19%	Explore
endothelial cell of vascular tree	12 studies	29% ± 10%	Explore
capillary endothelial cell	10 studies	39% ± 12%	Explore
endothelial cell of artery	9 studies	36% ± 11%	Explore
vein endothelial cell	9 studies	29% ± 11%	Explore
endothelial cell of lymphatic vessel	7 studies	29% ± 6%	Explore
innate lymphoid cell	7 studies	37% ± 14%	Explore
platelet	7 studies	21% ± 3%	Explore
effector CD8-positive, alpha-beta T cell	7 studies	42% ± 11%	Explore
myeloid cell	7 studies	30% ± 11%	Explore
T follicular helper cell	7 studies	38% ± 10%	Explore
effector memory CD8-positive, alpha-beta T cell, terminally differentiated	6 studies	42% ± 14%	Explore
plasma cell	6 studies	29% ± 7%	Explore
effector CD4-positive, alpha-beta T cell	6 studies	39% ± 10%	Explore
fibroblast	6 studies	18% ± 2%	Explore
effector memory CD4-positive, alpha-beta T cell	6 studies	46% ± 14%	Explore
alveolar macrophage	5 studies	18% ± 2%	Explore
central memory CD8-positive, alpha-beta T cell	5 studies	46% ± 16%	Explore
basal cell	5 studies	21% ± 4%	Explore
exhausted T cell	5 studies	59% ± 15%	Explore
plasmablast	5 studies	29% ± 10%	Explore
leukocyte	5 studies	34% ± 14%	Explore
enterocyte	5 studies	25% ± 7%	Explore
pericyte	5 studies	23% ± 10%	Explore
lymphocyte	5 studies	32% ± 7%	Explore
immature B cell	5 studies	28% ± 9%	Explore
ionocyte	4 studies	36% ± 15%	Explore
neutrophil	4 studies	20% ± 2%	Explore
respiratory goblet cell	4 studies	27% ± 12%	Explore
secretory cell	4 studies	30% ± 6%	Explore
mononuclear phagocyte	4 studies	27% ± 6%	Explore
glomerular endothelial cell	4 studies	43% ± 7%	Explore
abnormal cell	4 studies	29% ± 8%	Explore
precursor B cell	4 studies	27% ± 8%	Explore
CD4-positive helper T cell	4 studies	34% ± 14%	Explore
T-helper 17 cell	4 studies	31% ± 9%	Explore
CD4-positive, alpha-beta cytotoxic T cell	3 studies	35% ± 15%	Explore
ciliated cell	3 studies	23% ± 6%	Explore
goblet cell	3 studies	25% ± 6%	Explore
pro-B cell	3 studies	20% ± 0%	Explore
epithelial cell	3 studies	30% ± 9%	Explore
intermediate monocyte	3 studies	49% ± 26%	Explore
type I pneumocyte	3 studies	19% ± 1%	Explore
T-helper 1 cell	3 studies	44% ± 10%	Explore
central memory CD4-positive, alpha-beta T cell	3 studies	45% ± 1%	Explore
double negative thymocyte	3 studies	53% ± 9%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	19 studies	39% ± 11%	Explore
lung	10 studies	27% ± 8%	Explore
intestine	6 studies	20% ± 2%	Explore
lymph node	4 studies	30% ± 7%	Explore
kidney	3 studies	41% ± 10%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	100%	9750.92	578 / 578	94%	59.25	1086 / 1155
kidney	99%	3539.98	88 / 89	95%	74.38	857 / 901
thymus	100%	3944.45	650 / 653	94%	45.47	568 / 605
intestine	98%	4765.79	942 / 966	96%	78.31	504 / 527
stomach	96%	2374.23	343 / 359	95%	56.62	272 / 286
uterus	100%	4269.33	170 / 170	91%	94.91	416 / 459
breast	100%	4356.99	459 / 459	87%	46.58	973 / 1118
prostate	99%	3377.40	243 / 245	78%	25.24	390 / 502
esophagus	92%	2024.79	1334 / 1445	84%	46.73	153 / 183
bladder	95%	2735.57	20 / 21	81%	66.47	406 / 504
adrenal gland	100%	2871.50	258 / 258	74%	25.85	171 / 230
liver	79%	1383.31	178 / 226	88%	56.66	356 / 406
skin	72%	2104.32	1306 / 1809	90%	74.88	426 / 472
ovary	87%	1554.75	157 / 180	59%	17.26	254 / 430
pancreas	27%	373.66	87 / 328	96%	73.23	170 / 178
brain	55%	787.21	1463 / 2642	51%	15.18	363 / 705
lymph node	0%	0	0 / 0	100%	187.28	29 / 29
spleen	100%	21136.12	241 / 241	0%	0	0 / 0
adipose	100%	4491.67	1203 / 1204	0%	0	0 / 0
peripheral blood	100%	13471.70	927 / 929	0%	0	0 / 0
blood vessel	99%	2851.28	1327 / 1335	0%	0	0 / 0
heart	96%	2130.54	825 / 861	0%	0	0 / 0
tonsil	0%	0	0 / 0	96%	89.16	43 / 45
eye	0%	0	0 / 0	57%	43.00	46 / 80
muscle	40%	476.70	321 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0002725	Biological process	negative regulation of T cell cytokine production
GO_0043323	Biological process	positive regulation of natural killer cell degranulation
GO_0002476	Biological process	antigen processing and presentation of endogenous peptide antigen via MHC class Ib
GO_0002486	Biological process	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent
GO_0043322	Biological process	negative regulation of natural killer cell degranulation
GO_0002729	Biological process	positive regulation of natural killer cell cytokine production
GO_0001916	Biological process	positive regulation of T cell mediated cytotoxicity
GO_0006955	Biological process	immune response
GO_0002728	Biological process	negative regulation of natural killer cell cytokine production
GO_0045953	Biological process	negative regulation of natural killer cell mediated cytotoxicity
GO_0002477	Biological process	antigen processing and presentation of exogenous peptide antigen via MHC class Ib
GO_0005615	Cellular component	extracellular space
GO_0009897	Cellular component	external side of plasma membrane
GO_0005886	Cellular component	plasma membrane
GO_0016020	Cellular component	membrane
GO_0031901	Cellular component	early endosome membrane
GO_0055038	Cellular component	recycling endosome membrane
GO_0009986	Cellular component	cell surface
GO_0000139	Cellular component	Golgi membrane
GO_0005783	Cellular component	endoplasmic reticulum
GO_0098553	Cellular component	lumenal side of endoplasmic reticulum membrane
GO_0030670	Cellular component	phagocytic vesicle membrane
GO_0042612	Cellular component	MHC class I protein complex
GO_0012507	Cellular component	ER to Golgi transport vesicle membrane
GO_0005765	Cellular component	lysosomal membrane
GO_0032398	Cellular component	MHC class Ib protein complex
GO_0071889	Molecular function	14-3-3 protein binding
GO_0005102	Molecular function	signaling receptor binding
GO_0030881	Molecular function	beta-2-microglobulin binding
GO_0046979	Molecular function	TAP2 binding
GO_0005515	Molecular function	protein binding
GO_0046978	Molecular function	TAP1 binding
GO_0042605	Molecular function	peptide antigen binding

IV. Literature review

[source]

Gene name	HLA-F
Protein name	Major histocompatibility complex, class I, F HLA class I histocompatibility antigen, alpha chain F (CDA12) (HLA F antigen) (Leukocyte antigen F) (MHC class I antigen F) HLA-F protein (Major histocompatibility complex, class I, F) HLA class I histocompatibility antigen, alpha chain F MHC class I antigen MHC class I antigen (MHC class Ib antigen) MHC class I antigen (Major histocompatibility complex, class I, F) MHC class Ib antigen Nonclassical MHC class I antigen HLA class I histocompatibility antigen, alpha chain F (MHC class I antigen) HLA-F MHC class I antigen F HLA-F protein
Synonyms	RP3-377H14.1-002 HLAF RP3-377H14.1-001 HLA-5.4
Description	FUNCTION: Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors . Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production . Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions . May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses . May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity . .
Accessions	A0A1V0E3U1 ENST00000454779.5 A0A1V0E3W8 O78094 ENST00000440590.5 [P30511-2] A0A140T9D9 A0A890BYI6 A0A140T9D2 Q5JZ48 A0A140T9M4 A0A140T9W7 A0A1D5RMP3 D0EV57 ENST00000444891.5 A0A140T9W5 ENST00000550932.2 Q861E9 ENST00000444057.5 Q6DU20 A0A140T9W3 ENST00000259951.12 [P30511-3] A0A1V0E3U3 ENST00000420067.5 [P30511-2] A0A1V0E3X2 Q6DU28 ENST00000383515.6 [P30511-2] A0A140T9J8 A0A1V0E3U0 ENST00000452916.1 A0A0D9SF55 A0A1V0E3T9 ENST00000465459.2 P30511 Q861F0 ENST00000420923.5 Q7YP62 ENST00000430472.6 A0A0D9SFW8 A0A0G2JNV5 ENST00000437020.5 ENST00000435058.5 ENST00000552082.2 A0A140T9P9 ENST00000334668.8 [P30511-1] ENST00000342322.8 A0A140T908 ENST00000434407.6 [P30511-2] ENST00000551832.2 A0A140T9C8 ENST00000445657.6 ENST00000425139.1 ENST00000437226.1 ENST00000418017.5 ENST00000359076.7 [P30511-2] A0A0G2JH66 A0A140T9V0 ENST00000551780.2 ENST00000441200.5 ENST00000376861.5 [P30511-1] Q54A71 ENST00000447400.5 ENST00000426470.1 ENST00000454646.5 A0A1V0E3V1 ENST00000433515.5 A0A140T9K3 A0A140T9S6 ENST00000549422.2 ENST00000613731.2 ENST00000622145.4 ENST00000420414.5 A0A1V0E3W4 ENST00000475996.1 A0A0G2JPA3 A0A140T9C2 A0A140T9I8 A0A140T939 ENST00000422711.5 A0A140T9B7 A0A140T9A3 ENST00000383626.6 ENST00000376848.8 [P30511-2] ENST00000428296.6 H0Y4J4 A0A140T9X6 ENST00000458026.1 ENST00000376844.8 A0A140T8X0 Q5JZ47 ENST00000444621.1 ENST00000422439.5 ENST00000383627.8 A0A3G2C0L7 A0A346MPT4 ENST00000448064.1 ENST00000383516.8 ENST00000420024.5 A0A1V0E3V5 ENST00000426675.5 ENST00000414958.5 A0A140T925

HLA-F report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review